Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RBC Capital Downgrades Sarepta Therapeutics to Sector Perform, Lowers Price Target to $142

Author: Benzinga Newsdesk | May 28, 2024 06:13am
RBC Capital analyst Brian Abrahams downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Outperform to Sector Perform and lowers the price target from $157 to $142.

Posted In: SRPT